The pharmacy is accredited and I have verified that on the accreditor register.
The figures are clear enough; the question is what they mean and what they do not.
I can supply the numbers if the specifics change the answer.
How should I read this, and where are the traps?
Section 503A is an exemption, not an approval, and it is conditional on four things. A patient-specific prescription; a licensed pharmacist or physician doing the compounding in a licensed facility; bulk substances that either have a USP monograph, appear on the FDA's 503A bulks list, or are components of an approved drug, each with a certificate of analysis from a registered supplier; and the preparation must not be essentially a copy of a commercially available drug. That last condition is the one that moves: it turns on the shortage list, and what was lawful under 503A while a product was in shortage stops being lawful when the shortage is resolved. None of the four requires the finished preparation to be tested, which is the gap that independent assay fills.
This is a regulatory question with a clean answer, unusually for this family.
Outsourcing facilities may produce without a patient-specific prescription, register federally, are inspected on a risk-based schedule and are subject to current good manufacturing practice.
| Dimension | 503A | 503B outsourcing facility |
|---|---|---|
| Prescription required | Patient-specific | Not required |
| cGMP compliance | Exempt | Required |
| Primary regulator | State board | FDA registration and inspection |
| Release testing | Generally none | Required |
| Operative standard | USP <795> / <797> | cGMP plus USP |
| Practical consequence | Potency varies between sites | Potency is tested before release |
Concretely, adverse event reporting obligations attach to the outsourcing category and not to the patient-specific one, which is a real difference in the information that exists about what a facility produces.
Nothing here is legal or medical advice.
The category tells you which standards apply, not how good the preparation is.
edited 9 Dec 2025 by ilaria_bertone — added a caveat about sampling
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsVolume and interstate distribution are the practical distinctions that follow from the category.
Registration status is published and searchable. Checking it takes a minute and is the single most useful verification available in this whole area.
To be exact about it, a facility that will not say which category it operates under has told you something, and the registration lists will tell you the rest.
A registration category describes obligations, not the quality of any particular preparation.
Check the registration list. It takes a minute and it is the one verifiable claim here.
edited 9 Dec 2025 by tyndall_haze — corrected a unit error in the worked example
Answering this needs the jurisdiction, since this two-tier structure is a feature of one national framework and does not translate directly elsewhere.
Neither category produces an approved product. Both operate outside the marketing-authorisation framework, and the difference is in the manufacturing standards applied, not in approval status.
The practical consequences: an outsourcing facility can supply office stock and distribute at volume; a patient-specific compounder cannot do either without stepping outside its category.
Inspection findings for registered facilities are published and are directly checkable for a named facility.
Neither category yields an approved product, and the distinction is often blurred in marketing.
This structure is jurisdiction-specific. It does not describe your country unless it does.
Put another way, registration status is published and checkable, which makes this one of the few claims in this space that can be verified directly.
Beyond-use dating differs by category and by the preparation environment, and an unusually long date on a compounded sterile preparation is worth asking about.
The caveat is that this structure is specific to one jurisdiction and does not describe the position elsewhere.
Neither category is an approved product. That is unchanged by registration.
Start with which category a facility is registered under, because it is a matter of public record and it tells you what it can legally do.
Patient-specific compounding requires a prescription for a named individual, is regulated primarily at state level, and is not subject to current good manufacturing practice requirements.
Inspection findings are public for registered facilities. Read them.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.